Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacific Biosciences of California, Inc. on July 31, 2018, covering events occurring on July 27, 2018. The filing primarily addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel appointments rather than financial performance.
Material Changes
The material change reported is the appointment of Christian O. Henry as a Class I director, effective July 27, 2018. Mr. Henry brings significant experience from Illumina, Inc., where he served in various executive roles including Executive Vice President & Chief Commercial Officer and Chief Financial Officer.
Guidance, Outlook, and Compensation
- Director Compensation: Mr. Henry will receive an annual retainer of $35,000.
- Equity Grant: Mr. Henry was automatically granted a stock option to purchase 35,000 shares of common stock on the date of his appointment.
- Outlook: No financial guidance or management commentary regarding future business performance is included in this filing.
Investor Verification Checklist
- Verify the effective date of Mr. Henry's directorship (July 27, 2018).
- Confirm the terms of the stock option grant (35,000 shares) and annual retainer ($35,000).
- Review the attached press release (Exhibit 99.1) for additional context on the appointment.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial metrics.